Get the Stockscreener App
3.82
1.29%
-0.05
After Hours:
3.80
-0.02
-0.52%
Sab Biotherapeutics Inc stock is traded at $3.82, with a volume of 789.78K.
It is down -1.29% in the last 24 hours and down -2.80% over the past month.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses. The company's candidate, SAB-142 is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of type 1 diabetes (T1D).
See More
Previous Close:
$3.87
Open:
$3.83
24h Volume:
789.78K
Relative Volume:
1.51
Market Cap:
$268.45M
Revenue:
$114.70K
Net Income/Loss:
$-12.82M
P/E Ratio:
-1.4288
EPS:
-2.6735
Net Cash Flow:
$-45.71M
1W Performance:
+3.24%
1M Performance:
-2.80%
6M Performance:
+81.90%
1Y Performance:
+135.80%
1-Day Range:
$3.78
$3.94
1-Week Range:
$3.69
$3.99
52-Week Range:
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Name
Sab Biotherapeutics Inc
Sector
Industry
Phone
305-845-2813
Address
777 W 41ST ST, MIAMI BEACH
Compare SABS vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
3.82 | 271.97M | 114.70K | -12.82M | -45.71M | -2.6735 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Initiated | Guggenheim | Buy |
| Sep-17-25 | Initiated | Leerink Partners | Outperform |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Oct-09-24 | Initiated | Craig Hallum | Buy |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Nov-05-21 | Initiated | Chardan Capital Markets | Buy |
View All
Sab Biotherapeutics Inc Stock (SABS) Latest News
SAB Biotherapeutics (SABS) CMO has common shares withheld for taxes - Stock Titan
SAB Biotherapeutics - Global Legal Chronicle
[SCHEDULE 13D/A] SAB B... - Stock Titan
SAB Biotherapeutics Completes $85 Million Public Offering - Global Legal Chronicle
SAB Biotherapeutics closes $85 million public offering - The Pharma Letter
SAB Biotherapeutics (SABS) to Release Earnings on Friday - MarketBeat
SAB Biotherapeutics announces public stock offering; shares down - MSN
SAB Biotherapeutics Closes $85 Million Securities Offering - marketscreener.com
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - Weekly Voice
SAB BIO raises $85 million to fund diabetes drug trials - Stock Titan
SAB Biotherapeutics (SABS) raises $69.7M net to advance SAB‑142 clinical program - Stock Titan
SAB Biotherapeutics Launches Major Equity Financing Offering - TipRanks
SAB Biotherapeutics (NASDAQ: SABS) to raise $85M for SAB-142 trials - Stock Titan
SAB Biotherapeutics Prices Underwritten Equity Offering; About $69.7 Million Net Proceeds Expected - TradingView
Stock Recap: Is SAB Biotherapeutics Inc being accumulated by smart money2026 Market Outlook & Low Volatility Stock Recommendations - baoquankhu1.vn
Guggenheim initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation - MSN
SAB Biotherapeutics prices $85M stock offering at $3.85/share By Investing.com - Investing.com South Africa
SAB Biotherapeutics prices $85M stock offering at $3.85/share - Investing.com
Sab Bio announces pricing of $85 million public offering of common stock at $3.85 per share - marketscreener.com
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
SAB Biotherapeutics, Inc. Prices Public Offering of Common Stock and Pre-Funded Warrants to Raise Approximately $85 Million - Quiver Quantitative
SAB BIO plans $85M funding push for experimental type 1 diabetes treatment - Stock Titan
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - Benzinga
SAB Biotherapeutics (SABS) to offer common stock and pre-funded warrants - Stock Titan
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Biotech SAB BIO plans stock sale to fund Type 1 diabetes trials - Stock Titan
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update - MarketBeat
Commodore Capital LP Takes Position in SAB Biotherapeutics, Inc. $SABS - MarketBeat
SAB Biotherapeutics (NASDAQ:SABS) Cut to “Strong Sell” at Zacks Research - Defense World
SAB Biotherapeutics reports early C-peptide signals in phase 1 trial - Investing.com Nigeria
SAB Biotherapeutics (NASDAQ:SABS) Downgraded to Strong Sell Rating by Zacks Research - MarketBeat
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
SAB Biotherapeutics (NASDAQ:SABS) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), SAB Biotherapeutics (SABS) and Encompass Health (EHC) - The Globe and Mail
SAB Biotherapeutics (NASDAQ:SABS) Stock Price Expected to Rise, Chardan Capital Analyst Says - Defense World
Chardan Capital Raises SAB Biotherapeutics Price Target to $14 - National Today
Chardan Capital Raises SAB Biotherapeutics (NASDAQ:SABS) Price Target to $14.00 - MarketBeat
H.C. Wainwright cuts SAB Biotherapeutics price target to $7 on dilution - Investing.com
SAB Biotherapeutics (NASDAQ:SABS) Given New $7.00 Price Target at HC Wainwright - Defense World
SAB Biotherapeutics Announces Positive Phase 1 Results for SAB-142 Showing C-Peptide Preservation in Adult Type 1 Diabetes Patients - Minichart
SAB Biotherapeutics, Inc. 2024 Annual Report: Business Overview, Pipeline, and Strategic Outlook - Minichart
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes - National Today
SAB Biotherapeutics (NASDAQ:SABS) Price Target Cut to $7.00 by Analysts at HC Wainwright - MarketBeat
SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data - TipRanks
SAB Bio (SAB Biotherapeutics, Inc.) recently released further data from a Phase I clinical trial of its candidate drug SAB-142 in adult patients diagnosed with autoimmune type 1 diabetes. - Bitget
SAB Bio reports Phase 1 SAB-142 data showing C-peptide preservation signals in adult T1D cohort - TradingView
Phase 1 SAB-142 data from SAB BIO (Nasdaq: SABS) highlight early T1D signal - Stock Titan
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights - Investing News Network
SAB BIO backs diabetes therapy with $175M and 2027 trial goal - Stock Titan
SAB Biotherapeutics 10-K: Revenue $0, Net income $13.27M - TradingView
SAB Biotherapeutics (SABS) boosts cash with $175M raise and 2025 warrant gain - Stock Titan
Sab Biotherapeutics Inc Stock (SABS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):